Wednesday, March 4, 2015

Tuesday Features

Synergy Disc Replacement sets global sales plan

Synergy Disc Replacement sets global sales plan

After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution aggressively in Europe, Asia Pacific and other parts of the world. Devesh Menawat “We are also in the early stages of developing our U.S. regulatory strategy... [Read more of this feature]


In conversation with Steve Damon

In conversation with Steve Damon

Steve Damon As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He was responsible for executing several key partnerships with various pharmaceutical companies for Altea’s novel transdermal patch technology, bringing... [Read more of this feature]


Neovasc launching Reducer in Europe for RA

Neovasc launching Reducer in Europe for RA

Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. Alexei Marko “Our aim is have distributors selling Reducer in Switzerland, Italy and the UK, while in Germany, we’ll use a combination of distributors... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Avivagen advancing OxC-beta Livestock in poultry

Avivagen advancing OxC-beta Livestock in poultry

After reporting final results of a poultry trial that was run by Chonbuk National University in Korea, Avivagen (TSX-V:VIV) plans to move ahead with its OxC-beta Livestock supplement to confirm its broiler chicken results in the commercial operations of major poultry producers. “Additionally, it is our intention to evaluate the benefits of OxC-beta... [Read more of this brief]


HCW starts Bacterin International at buy

HCW starts Bacterin International at buy

H.C. Wainwright has initiated coverage of Bacterin International Holdings (NYSE MKT:BONE) with a “buy” rating and a 12-month price target of $5. The stock closed at $3.63 on Monday. Bacterin is one of the top four players in the $410-million U.S. demineralized bone matrix (DBM) market, with over 6% market share, writes analyst Swayampakula Ramakanth. Bacterin’s... [Read more of this brief]


Microbix launches new molecular diagnostic products

Microbix launches new molecular diagnostic products

Microbix Biosystems (TSX:MBX) has launched its first new products in the rapidly growing molecular diagnostics (MDx) quality control market and has already booked sales to customers responsible for institutional accreditation testing. The company also is preparing to sell these products directly to clinical laboratories, with a launch at industry trade... [Read more of this brief]


HCW starts uniQure at buy

HCW starts uniQure at buy

H.C. Wainwright has initiated coverage of uniQure N.V. (NASDAQ:QURE) with a “buy” rating and price target of $30, using a sum-of-the-parts analysis of Glybera EU and Glybera US. The stock closed at $23.24 on Friday. uniQure is the first company to receive regulatory approval for a gene therapy treatment in the West, a milestone that has helped... [Read more of this brief]


Transition completes enrollment with ELND005 in AD

Transition completes enrollment with ELND005 in AD

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has completed enrolment of the Phase 2 clinical study evaluating its neuropsychiatric drug candidate, ELND005, as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer’s disease (AD). It is anticipated that the top-line data from the Harmony AD Study will be announced... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+